Kornimate/medical-research-clean huggingface dataset:
the mechanism of extracellular vesicles containing mitochondrial dna in ards lung injury caused by extrapulmonary sepsis

Conditions: ARDS, Human

Summary: the acute respiratory distress syndrome (ards) remains a common and morbid complication of critical illness. sepsis contribute to a lot of ards cases, but mechanisms by which non-pulmonary insults such as extrapulmonary sepsis propagate lung injury remain unclear. most eukaryotic cells release small anuclear membrane-bound vesicles into the extracellular environment in either physiological or pathophysiological conditions, often called extracellular vesicles (evs) .through their cargo containing bioactive molecules such as proteins, mrnas, and micrornas and their interaction with target cells, evs are recognized as important mediators of cellular communication. mitochondrial contents are clearly present in evs, and mitochondrial cargo within evs have been shown to stimulate the production of proinﬂammatory cytokines, further enhancing lps-induced inﬂammation. among the mitochondrial contents, mtdna was present at higher levels in evs.therefore, we hypothesis, evs containing mtdna play an important role in the occurrence and development of ards caused by extrapulmonary sepsis.

inclusion criteria: patients with ards caused by abdominal infection exclusion criteria: age \<18 years old or pregnancy; death or discharge within 24 hours after admission; advanced tumor the pathological information of the patients was collected on 24h, 48h after admission including demographic data, acute physiology and chronic health evaluation (apache) ii score , number of organ failures included in the sequential organ failure assessment (sofa) score. the levels of lactate and inflammatory mediators (i.e., plasma c-reactive protein and procalcitonin) were detected on 24h and 48h after admission. all patients were followed up for 28 days, and all-cause mortality was recorded. the durations of mechanical ventilation and icu stay were also recorded. the primary outcome was mortality on day 28. secondary outcomes included the ventilator days and icu length of stay. peripheral blood samples (2 ml) were collected on 24h and 48h after admission to the icu. evs were isolated from the plasma, and mtdna concentration of plasma dna was evaluated by rt-qpcr.

Eligibility criteria:
inclusion criteria: patients with ards caused by abdominal infection exclusion criteria: age \<18 years old or pregnancy; death or discharge within 24 hours after admission; advanced tumor
endoscopic combined intrarenal surgery vs. percutaneous nephrolithotomy for treatment of staghorn calculi

Conditions: Urinary Calculi

Summary: this is a prospective randomized study to compare endoscopic combined intrarenal surgery and pcnl as modalities of treatment for staghorn stones. in terms of efficacy and safety

this is a prospective randomized study to compare endoscopic combined intrarenal surgery and pcnl as modalities of treatment for staghorn stones. in terms of efficacy and safety the efficacy will be studied at stone-free rate while efficacy will be studied using dmsa scan pre- and post-procedures in addition to the safety of each procedure with regard to intra- and post-operative complications,.

Eligibility criteria:
inclusion criteria: * patients are more than 18 and less than 65 years old. * patients with renal staghorn stones based on imaging modalities (stones occupying the renal pelvis and extending into at least 2 major calyces). exclusion criteria: * patients with renal insufficiency (serum creatinine \> 1.6 mg/dl) * patients with active urinary tract infection. * patients with congenital renal anomalies. * morbid obesity (bmi \> 35 kg/m2). * pregnancy. * bleeding coagulopathy. * skeletal deformity
full-thickness skin vs. synthetic mesh in the repair of large incisional hernia

Conditions: Ventral Hernia; Postoperative Pain

Summary: this is a prospective randomized study to compare surgical methods for the repair of large abdominal hernia.

patients with giant (\>10 cm in diameter) abdominal wall hernia are included in a prospective randomized study comparing conventional mesh repair with the best possible method to onlay full thickness skin grafts.

Eligibility criteria:
inclusion criteria: * ventral hernia \> 10 centimeters, abdominal wall pain or discomfort, desire hernia repair. exclusion criteria: * \< 18 years of age, ongoing pregnancy or nursing, ongoing immunosuppressive treatment,ongoing smoking.

Keywords: ventral hernia postoperative pain ventral hernia pain questionnaire postoperative abdominal wall and muscle function biodex
genetic epidemiology--development of cardiovascular risk

Conditions: Cardiovascular Diseases; Hypertension; Obesity; Heart Diseases

Summary: to determine how genetic and environmental factors influence the co-occurrence of obesity and hypertension during development and to identify cardiovascular risk factors in adolescence that will predict cardiovascular disease in adults.

background: obesity and hypertension are two of the major risk factors for cardiovascular disease (cvd) and those with obesity have a greater risk of hypertension. in children and adolescents, high body mass index correlates with elevated blood pressure. genetic factors make a significant contribution to the variation of obesity and hypertension. design narrative: anthropometric, cardiovascular, physiologic and physical fitness data were used to investigate a series of critical issues about the etiology, heterogeneity, comorbidity and developmental trajectories of cvd risk factors, including obesity, hypertension and cardiovascular health. using the two datasets, the main questions of the study were addressed. how do genes and environment act and interact to create covariation between obesity and hypertension, and were the genetic and environmental factors the same at all ages (from childhood to late adolescence and adulthood) in both sexes? areas of research included the following: causes of individual differences in anthropometric and cardiovascular characteristics, their covariation and developmental change or continuity in adolescence, parent-offspring transmission, prediction of cardiovascular risk, and sex, race and population differences in genetic and environmental contributions on cardiovascular risk factors.

Eligibility criteria:
no eligibility criteria
effect of a fortified balanced energy-protein supplement on birth outcome and child growth in houndé district, burkina faso.

Conditions: Small for Gestational Age at Delivery; Low Birth Weight; Prematurity; Infant Malnutrition

Summary: the 2016 who antenatal care guidelines stated that pregnant women in undernourished populations should receive fortified balanced energy-protein (bep) supplements to reduce the risk of stillbirth and small-for-gestational-age birth. however, acceptable supplements and delivery channels must be determined for different contexts. the present proposal therefore will 1) perform a formative study to identify the most suitable (acceptability and utilization) bep supplement for pregnant women in rural burkina faso (phase 1) and 2) evaluate the efficacy of this supplement to improve birth weight, fetal and infant growth (phase 2). the nutritional composition of the bep supplement was established during an expert convening at the bmgf in september 2016. private sector partners will prepare the supplements in the selected forms with the recommended nutrient composition.

pregnancy remains a challenging period in the life of many women in low- and middle-income countries. maternal mortality remains high and many newborns suffer from premature delivery and /or gestational growth retardation both in length and in weight accumulation. the 2016 who antenatal care guidelines stated that pregnant women in undernourished populations should receive fortified balanced energy-protein (bep) supplements to reduce the risk of stillbirth and small-for-gestational-age birth. however, acceptable supplements and delivery channels must be determined for different contexts. the purpose of this study is to assess the efficacy of a fortified bep supplement for pregnant and lactating women to improve birth weight, fetal and infant growth. this research includes 2 phases: * phase 1 - part 1: formative research to identify preferred product types of a fortified bep supplement; * phase 1 - part 2: formative research with a 10-week home-feeding trial to determine the acceptability of a fortified bep supplement for longer-term consumption. * phase 2: a community-based, individually randomized efficacy trial of the fortified bep food supplement including 1,776 pregnant and lactating women aimed at testing 2 hypothesis: supplementing pregnant and lactating women with a fortified bep supplement will improve fetal growth; improving fetal growth will have a positive effect on health and growth during infancy.

Eligibility criteria:
inclusion criteria: * participant age (15-40 years). * pregnant as determined by a pregnancy test and confirmed by ultrasound. * women who signed the informed consent form (in case of minors the parents or husband signs) exclusion criteria: * women planning to leave the area before delivery. * women who plan to deliver outside the area. * pregnancies with a gestational age \> 20 weeks at study inclusion. * women with multi-fetal gestation (exclusion from analysis). * women who are allergic to peanuts.
dosimetric comparison of doses in both positions (prone and decubitus) for patient with breast cancer

Conditions: Breast Cancer

Summary: compare dosimeters in both positions (prone and decubitus) for each patient

quantitative physics: dosimetric comparison of doses in target volumes and organs at risk. the technique used is that of which the dose on the organs at risk is as low as possible, and whose dose to the target volume is the closest possible to the prescribed dose (100% of the prescribed dose).

Eligibility criteria:
inclusion criteria: * patients with primary breast cancer and in whom conservative post- surgery radiation therapy for breast cancer is prescribed. * patients aged over 18 years * patients with indication for conservative surgery. * resection should be in healthy margin. * women of childbearing potential must satisfy a negative pregnancy test at the screening visit and use effective contraception as determined by the physician of the patient throughout the study. exclusion criteria: * minor patient * patients whose tumor resection is incomplete * patients with an indication of mastectomy * patients with a history of radiation therapy of the chest * pregnant women, lactating, or of childbearing age without effective contraception. * patients who had more than 4 scanners in one year. ( scanner cervical , thoracic, or abdominal * patients with an incompatible condition with monitoring protocol (psychiatric disorder, uncontrolled disease). * patient unable to respond to a questionnaire
telepremie: telehomecare for step-down care post-nicu discharge

Conditions: Anxiety; Self Efficacy

Summary: telehealth is a means of providing care from a distance, at the convenience of the patient. this study will be testing the addition of telehealth visits (th) to the standard of care (soc) following discharge from the neonatal intensive care unit (nicu). this study will be used to determine whether telehealth appointments post-nicu discharge can improve the experiences of parents in caring for their infant and reduce the number of health care visits they have with their infant within three months post-nicu discharge. participants in this study will be randomly assigned to two groups. one group will receive the standard of care, which means they will have an appointment in place with a primary care provider, pediatrician or return visit to the nicu post discharge. the second group will have the standard of care described above and two telehealth visits within the first week at home with their infant. the study will explore the experiences of parents of nicu infants following their discharge from nicu, both those receiving standard of care (soc) and the telehealth monitoring intervention. participants will be required to complete surveys online at 5 time periods: when parents decide to be part of the study, prior to discharge from nicu, 1 day after discharge, 2 days following the primary care provider visit and at 3 months following discharge from nicu. the questionnaires used will measure parental anxiety levels and parental confidence. the number of infant visits to the primary care provider, pediatrician, emergency department and nicu will also be collected at three months post-nicu discharge. a subset of participants (from both soc and th groups) will further participate in semi-structured interviews about their experiences in the nicu and caring for their children after discharge. nicu clinicians who consent will participate in semi-structured interviews about their experiences with the telehealth intervention. the cost-effectiveness of the telehealth intervention will be analysed in comparison to soc.


Eligibility criteria:
inclusion criteria: * parent-infant pairs admitted to neonatal intensive care unit where study is conducted. * parent has internet access. * parent has literacy level such that they are comfortable reading and filling out surveys. * infant is likely to survive. exclusion criteria: * infant discharged to foster care. * infant transferred or discharged within 3 days of admission to neonatal intensive care unit.

Keywords: neonatal intensive care telehealth anxiety self efficacy parenting/psychology
a study to extend efficacy and safety of shr-1819 injection in adult patients with moderate to severe atopic dermatitis

Conditions: Moderate to Severe Atopic Dermatitis

Summary: this study is a multicenter, open-label, extended study to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of shr-1819 injection in adult subjects with moderate to severe atopic dermatitis who have previously participated in the shr-1819 injection study for atopic dermatitis (defined as the main study, referred to as the main study hereinafter).


Eligibility criteria:
inclusion criteria: 1. the age of 18\~75 years old at the time of signing the informed consent form (including the values at both ends), gender is not limited； 2. previous atopic dermatitis, (1) participation in a complete main study; or (2) subjects who prematurely terminate primary study therapy for reasons other than shr-1819 injection are required to complete a last safety follow-up or withdrawal from the visit, and the investigator assesses that the influencing factor has been eliminated/no longer affects the participant's participation in the extended study. participants were required to meet the main study inclusion criteria for the main study； 3. be able to apply a topical emollient (moisturizer) continuously for at least 7 consecutive days before the first dose and continue to use it for the duration of the study; 4. be able to sign informed consent forms, understand and agree to follow the requirements of the study and the trial process. exclusion criteria: 1. pregnant or lactating women； 2. female subjects of childbearing potential and male subjects whose partners are women of childbearing age have a plan to donate sperm/eggs from the signing of the informed consent form until 3 months after the last dose of the trial drug, or refuse to comply with the relevant contraceptive requirements; 3. a history of alcohol abuse or illicit drug abuse within 6 months prior to screening; 4. hypersensitivity to the study drug or any ingredient in the study drug； 5. diagnosed within 6 months prior to screening or judged by the investigator to have a suspected immunosuppressive disease; 6. oral or parenteral systemic antimicrobials are used within 2 weeks before the first dose； 7. suspected or confirmed active tuberculosis (tb); 8. have malignancy or history of malignancy prior to screening； 9. major surgery was performed within 3 months prior to screening, or major surgery was planned during the study； 10. there are currently significant abnormal laboratory test results, severe concomitant diseases, and other circumstances that the investigator considers inappropriate to participate in this trial; 11. there were treatment-related adverse events leading to discontinuation of treatment and study drug-related saes in the main study, and the investigator or sponsor medical department considered that continuing to participate in extended therapy would pose an unacceptable safety risk to participants.
the role of amniotic membrane transplantation in ocular chemical burns

Conditions: Eye Burns

Summary: this is a randomized clinical trial study to identify the role of amt (amniotic membrane transplantation) in treating epithelial defect, symblepharon prevention preventing corneal vascularization and opacity decreasing pain and improving visual acuity, and patients with acute chemical burns.

the study is on patients with grade ii-iv acute ocular chemical burns (roper - hall classification) in the first 2 weeks of injury. after topical anesthesia, all patients initially will receive first aid therapy; which included irrigation with normal saline to normalize ocular surface ph and removal of early particulate maeuil and debris. after complete examination and obtaining informed consent, the patients will be randomized using a treatment assignment list to either amt with conventional medical therapy (group a) or medical treatment only (group b). in the patients with bilateral injuries the eyes will be randomized separately. amt will be performed within 24h of presentation. amniotic membrane will remain in place for 7-14 days. the patients will be examined at days 1, 3, 7, 10, 14, 21, 28 and then biweekly until 3 months and monthly until (1 year in every visit, visual acuity (by sneillen charts), reduction of pain (subjectively) size of corneal epithelial defect (by fluorseein satiny extent of corneal vascularization and opacity, and symblepharon formation will be assessed. digital photographs at each visit will be obtained.

Eligibility criteria:
inclusion criteria: * patients with chemical eye burn grade 2-4 * burning has been occurred in 2 weeks exclusion criteria: * grade i burnings * more than 2 weeks have passed of burning * follow up of the patients has been disconnected in 6 month

Keywords: amniotic membrane transplantation ocular chemical burns
effects of fluid milk in attenuating hyperglycemia and hypertriglyceridemia after meal

Conditions: Oral Glucose Tolerance Test; High Fat Tolerance Test

Summary: epidemiological studies indicate that risk of type 2 diabetes is lower when milk is consumed in the regular diet. milk products are unique in that they produce high insulin response despite their low glycemic index. the general aim of the proposed study is to determine the effect of fluid milk on attenuating the postprandial surge in plasma glucose and triglyceride after meals and its associated physiological mechanisms. the investigators hypothesize that the consumption of one or two servings of non-fat milk added to a standard oral glucose tolerance test (ogtt) solution or the high fat tolerance test meal will attenuate postprandial hyperglycemia and triglyceridemia. the investigators hypothesize that the postulated improvement in postprandial metabolic response due to the consumption of fluid milk will be associated with increased postprandial insulin secretion as well as insulin-mediated endothelial vasodilation and whole-limb perfusion.

a double blind randomized placebo-controlled crossover experimental design with six treatments will be used. a total of 30 young (20-40 year old) healthy men and women will serve as subjects. following 2 days of physical activity and dietary control, subjects will consume a standard ogtt load or high fat tolerance load on the morning of day 3. the solution used in the meals will be mixed with one or two servings of non-fat milk or placebo (either carbohydrate matched or total calorie matched). before and after the test meals are consumed, blood samples will be obtained for later analysis of glucose, triglycerides, insulin, and inflammatory cytokines and brachial artery flow-mediated dilation and femoral artery vascular conductance will be measured. the present research project should provide new and clinically useful insight into the role of conventional dairy products on metabolic homeostasis. if the working hypotheses are supported, the information could be used as an initial/preliminary basis for recommendations for the consumption of fluid milk in the prevention of metabolic diseases.

Eligibility criteria:
inclusion criteria: * apparently health, sedentary. all subjects will have a bmi of 25-35 kg/m2. exclusion criteria: * candidates who are taking cardiovascular-acting drugs will not be eligible for participation. subjects with significant intima-media thickening, plaque formation, characteristics of atherosclerosis, metabolic diseases, gastrointestinal disorders, and/or renal disease will be excluded from the study. additional exclusion criteria will be cow milk allergy or lactose intolerance, pregnancy or lactation, and alcohol abuse.

Keywords: endothelial dependent vasodilation blood flow blood glucose triglycerides non-fat milk dairy
safety and performance of hirestm ultra/ultra 3d cl mid-scala electrodes in adults with severe-to-profound hearing loss

Conditions: Cochlear Hearing Loss

Summary: this is a prospective study designed to evaluate the safety and performance of the hirestm ultra cl hifocustm ms electrode and hirestm ultra 3d cl hifocustm ms electrode (ultra x) under normal conditions of use as it is approved for this device.

this study is set up to document any adverse events and comparing pre- to post-implant benefit to subjects. any adverse events associated with the device will be documented via advanced bionics complaint handling system for the lifetime of the device. a within-subjects repeated-measures design will be employed. speech perception will be evaluated preoperatively with conventional amplification to determine candidacy and to establish baseline performance. efficacy parameters are speech perception data which will be collected according to clinical routine with a 6 month follow up period. subjects will be implanted unilaterally with the ultra x according to standard clinical care. the primary efficacy objective is to demonstrate that mean monosyllabic word recognition score with the ultra x used in combination with a sound processor programmed with the latest fitting software six months after activation is at least 20% better than the mean word score at baseline with conventional amplification in the same ear. the primary efficacy endpoint is reached six months after device activation.

Eligibility criteria:
inclusion criteria: * no previous experience with any auditory implant * 18 years of age or older * postlingual onset of severe hearing loss (≥ 4 years of age) * limited benefit from appropriately fitted hearing aids, defined as scoring 60% or less in freiburger monosyllabic word test * german language proficiency * willingness to participate in all scheduled procedures outlined in the protocol exclusion criteria: * cochlear malformation or obstruction that would preclude full insertion of electrode array. * presence of additional disabilities that would prevent or interfere with participation in the required study procedures * medical or psychological conditions that contraindicate surgery or impact the ability to manage an implanted device or the study related procedures * evidence of central auditory lesion or compromised auditory nerve * pregnancy at time of surgery.